CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Switching from Reference to Biosimilar Adalimumab for Patients with Various Inflammatory Conditions

Last updated: February 16, 2021
Project Number: RB1552-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with rheumatoid arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, or uveitis?
  2. What is the clinical effectiveness of switching from reference to biosimilar adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis?

Key Message

Ten randomized controlled trials and 4 non-randomized studies were identified regarding the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with rheumatoid arthritis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, or psoriatic arthritis. No evidence was identified regarding the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with uveitis or ankylosing spondylitis and in pediatric patients with polyarticular juvenile idiopathic arthritis.